Armata reveals detailed structure of phage P7-1, advancing treatment for antibiotic-resistant infections.

Armata Pharmaceuticals published a study detailing the structure of phage P7-1, part of their AP-PA02 cocktail targeting Pseudomonas aeruginosa infections in cystic fibrosis and bronchiectasis patients. Using advanced cryo-electron microscopy, the research uncovered how P7-1's unique tail fibers contribute to its stability and infection mechanism. This insight supports Armata's development of phage therapies as alternatives to antibiotics, with AP-PA02 showing promise in Phase 2 trials. The findings pave the way for engineering more effective and stable phage treatments against resistant bacterial infections.